The move follows the cGMP inspection by the Dutch authorities.
TiGenix CEO Eduardo Bravo said the state-of-the-art manufacturing site is responsible for the production of innovative cell therapy products.
"It provides us with crucial manufacturing capabilities to support the anticipated growth in demand for ChondroCelect for cartilage repair, and has sufficient capacity for the production of our advanced stem cell therapy products," Bravo added.
TiGenix is a cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs.